The Life Sciences and Technology teams advised Delphia Therapeutics on the closing of its $67 million Series A financing led by premier early life sciences investors including GV (Google Ventures), Nextech Invest, Polaris Innovation Fund and Alexandria Venture Investments.
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia's activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
The Goodwin team was led by Jake Hays, Sumin Seo and Kingsley Taft (Corporate) and included Charles Li and Gozde Guckaya (Global Trade) and Dan Karelitz (Tax).
For additional details on the financing, please read the press release and coverage in Endpoints and GEN Edge.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.